Company News

Axio Biosolutions expands its operations to UK

Views: 1.1K
Leo Mavely, CEO of Axio

Leo Mavely, CEO of Axio

Strengthening its presence across the globe, Axio Biosolutions, a medtech company has planned to expand its operations to UK. Reinforcing its commitment, company will address the unmet wound care challenges across the globe with its existence in thirteen countries including Europe, Middle-East and Africa.

Funded by Accel Partners, IDG Ventures and GVFL, Axio is globally known for using innovative medical technology to create breakthrough products and save people’s lives.

Company will also be launching the award winning and CE approved, Axiostat its flagship product in UK market through The Emergency Services Show, scheduled on 21st and 22nd September 2016 and Trauma Innovation UK, which is Europe’s Largest Forum for military and emergency medicine scheduled on 27th and 28th September 2016.

Speaking on the occasion, Leo Mavely, CEO of Axio said, ‘Axiostat has been saving lives of accident victims and defense forces for many years now in India and world-over. We are delighted to expand our presence and bring Axiostat to UK & European Market. With our partner – Western Medical Supplies UK we expect to serve a large market, which has shown a lot of demand for effective haemostatic products.”

Uncontrolled bleeding is one of the leading causes of death from traumatic injuries. With growing number of accidents, increased conflicts, nascent or non-existent pre-hospital care, an effective haemostat has become an inevitable first-aid tool for emergency services across the globe.

Axiostat is regularly used by Indian Armed forces, BSF, NSG, and other para-military forces, as part of their defense kit, during their operations at the border and conflict zones such as North-East.

Axio’s customers also include numerous government hospitals and reputed private institutions such as AIIMS, Manipal, Apollo, Breach Candy and Fortis. In the $1.7 billion global haemostat market, which is expected to become $2.5 billion by 2020, Axio today is a name to reckon with.

The company’s vision is to become the first choice for any customer looking for advanced, affordable wound care solutions worldwide. To make that happen, Axio has a fully functioning modern Research and Development (R&D) wing registered in Bangalore with a GMP, ISO 13485 manufacturing facility situated in Ahmedabad, Gujarat.

Recommended from all portals

Latest News

To Top